

Hepatocellular Carcinoma Drugs Market Size, Trends, Analysis, and Outlook By Drug Class (PD-1/PD-L1 Inhibitors, Atezolizumab, Avelumab, Durvalumab, Tyrosine Kinase Inhibitors, Gefitinib, Erlotinib, Sorafenib), By Treatment (Medication, Surgery, Radiotherapy, Chemotherapy, Others), By Route of Administration (Oral, Injectable, Others), By End-User (Hospitals, Homecare, Specialty Clinics, Others), By Distribution Channel (Hospital Pharmacy, Online Pharmacy, Retail Pharmacy), by Region, Country, Segment, and Companies, 2024-2030

<https://marketpublishers.com/r/H431FAF6D7BBEN.html>

Date: March 2024

Pages: 190

Price: US\$ 3,980.00 (Single User License)

ID: H431FAF6D7BBEN

Abstracts

The global Hepatocellular Carcinoma Drugs market size is poised to register 7.65% growth (CAGR) from 2024 to 2030, presenting significant growth prospects for companies operating in the industry. The industry study analyzes the global Hepatocellular Carcinoma Drugs market By Drug Class (PD-1/PD-L1 Inhibitors, Atezolizumab, Avelumab, Durvalumab, Tyrosine Kinase Inhibitors, Gefitinib, Erlotinib, Sorafenib), By Treatment (Medication, Surgery, Radiotherapy, Chemotherapy, Others), By Route of Administration (Oral, Injectable, Others), By End-User (Hospitals, Homecare, Specialty Clinics, Others), By Distribution Channel (Hospital Pharmacy, Online Pharmacy, Retail Pharmacy).

The future of hepatocellular carcinoma (HCC) drugs is shaped by advancements in targeted therapies, immunotherapy, and combination treatment approaches aimed at improving survival outcomes and quality of life for patients with liver cancer. Key trends

include the development of molecularly targeted agents targeting key signaling pathways implicated in HCC pathogenesis, such as vascular endothelial growth factor (VEGF) inhibitors, multikinase inhibitors, and immune checkpoint inhibitors, which aim to inhibit tumor growth, angiogenesis, and metastasis while enhancing antitumor immune responses. Additionally, the exploration of combination therapies combining targeted agents with immunotherapeutic approaches, such as immune checkpoint inhibitors plus anti-angiogenic agents or cytokine-based therapies, aims to overcome treatment resistance and improve response rates in advanced HCC. Moreover, efforts to identify predictive biomarkers, optimize patient selection criteria, and integrate multidisciplinary care approaches, including locoregional therapies and surgical interventions, are essential for optimizing treatment outcomes and prolonging survival in patients with hepatocellular carcinoma..

Hepatocellular Carcinoma Drugs Market Drivers, Trends, Opportunities, and Growth Opportunities

This comprehensive study discusses the latest trends and the most pressing challenges for industry players and investors. The Hepatocellular Carcinoma Drugs market research analyses the global market trends, key drivers, challenges, and opportunities in the industry. In addition, the latest Future of Hepatocellular Carcinoma Drugs survey report provides the market size outlook across types, applications, and other segments across the world and regions. It provides data-driven insights and actionable recommendations for companies in the Hepatocellular Carcinoma Drugs industry.

Key market trends defining the global Hepatocellular Carcinoma Drugs demand in 2024 and Beyond

The industry continues to remain an attractive hub for opportunities for both domestic and global vendors. As the market evolves, factors such as emerging market dynamics, demand from end-user sectors, a growing patient base, changes in consumption patterns, and widening distribution channels continue to play a major role.

Hepatocellular Carcinoma Drugs Market Segmentation- Industry Share, Market Size, and Outlook to 2030

The Hepatocellular Carcinoma Drugs industry comprises a wide range of segments and sub-segments. The rising demand for these product types and applications is supporting companies to increase their investment levels across niche segments. Accordingly, leading companies plan to generate a large share of their future revenue

growth from expansion into these niche segments. The report presents the market size outlook across segments to support Hepatocellular Carcinoma Drugs companies scaling up production in these sub-segments with a focus on expanding into emerging countries.

Key strategies adopted by companies within the Hepatocellular Carcinoma Drugs industry

Leading Hepatocellular Carcinoma Drugs companies are boosting investments to capitalize on untapped potential and future possibilities across niche market segments and surging demand conditions in key regions. Further, companies are leveraging advanced technologies to unlock opportunities and achieve operational excellence. The report provides key strategies opted for by the top 10 Hepatocellular Carcinoma Drugs companies.

Hepatocellular Carcinoma Drugs Market Study- Strategic Analysis Review

The Hepatocellular Carcinoma Drugs market research report dives deep into the qualitative factors shaping the market, empowering you to make informed decisions-

Industry Dynamics: Porter's Five Forces analysis to understand bargaining power, competitive rivalry, and threats that impact long-term strategy formulation.

Strategic Insights: Provides valuable perspectives on key players and their approaches based on comprehensive strategy analysis.

Internal Strengths and Weaknesses: Develop targeted strategies to leverage strengths, address weaknesses, and capitalize on market opportunities.

Future Possibilities: Prepare for diverse outcomes with in-depth scenario analysis. Explore potential market disruptions, technology advancements, and economic changes.

Hepatocellular Carcinoma Drugs Market Size Outlook- Historic and Forecast Revenue in Three Cases

The Hepatocellular Carcinoma Drugs industry report provides a detailed analysis and

outlook of revenue generated by companies from 2018 to 2023. Further, with actual data for 2023, the report forecasts the market size outlook from 2024 to 2030 in three case scenarios- low case, reference case, and high case scenarios.

Hepatocellular Carcinoma Drugs Country Analysis and Revenue Outlook to 2030

The report analyses 22 countries worldwide including the key driving forces and market size outlook from 2021 to 2030. In addition, region analysis across Asia Pacific, Europe, the Middle East, Africa, North America, and South America is included in the study. For each of the six regions, the market size outlook by segments is forecast for 2030.

North America Hepatocellular Carcinoma Drugs Market Size Outlook- Companies plan for focused investments in a changing environment

The US continues to remain the market leader in North America, driven by a large consumer base, the presence of well-established providers, and a strong end-user industry demand. Leading companies focus on new product launches in the changing environment. The US economy is expected to grow in 2024 (around 2.2% growth in 2024), potentially driving demand for various Hepatocellular Carcinoma Drugs market segments. Similarly, Strong end-user demand is encouraging Canadian Hepatocellular Carcinoma Drugs companies to invest in niche segments. Further, as Mexico continues to strengthen its trade relations and invest in technological advancements, the Mexico Hepatocellular Carcinoma Drugs market is expected to experience significant expansion, offering lucrative opportunities for both domestic and international stakeholders.

Europe Hepatocellular Carcinoma Drugs Market Size Outlook-Companies investing in assessing consumers, categories, competitors, and capabilities

The German industry remains the major market for companies in the European Hepatocellular Carcinoma Drugs industry with consumers in Germany, France, the UK, Spain, Italy, and others anticipated to register a steady demand throughout the forecast period, driving the overall market prospects. In addition, the proactive approach of businesses in identifying and leveraging new growth prospects positions the European Hepatocellular Carcinoma Drugs market for an upward trajectory, fostering both domestic and international interest. Leading brands operating in the industry are emphasizing effective marketing strategies, innovative product offerings, and a keen understanding of consumer preferences.

Asia Pacific Hepatocellular Carcinoma Drugs Market Size Outlook- an attractive hub for opportunities for both local and global companies

The increasing prevalence of indications, robust healthcare expenditure, and increasing investments in healthcare infrastructure drive the demand for Hepatocellular Carcinoma Drugs in Asia Pacific. In particular, China, India, and South East Asian Hepatocellular Carcinoma Drugs markets present a compelling outlook for 2030, acting as a magnet for both domestic and multinational manufacturers seeking growth opportunities. Similarly, with a burgeoning population and a rising middle class, India offers a vast consumer market. Japanese and Korean companies are quickly aligning their strategies to navigate changes, explore new markets, and enhance their competitive edge. Our report utilizes in-depth interviews with industry experts and comprehensive data analysis to provide a comprehensive outlook of 6 major markets in the region.

Latin America Hepatocellular Carcinoma Drugs Market Size Outlook- Continued urbanization and rising income levels

Rising income levels contribute to greater purchasing power among consumers, spurring consumption and creating opportunities for market expansion. Continued urbanization and rising income levels are expected to sustainably drive consumption growth in the medium to long term.

Middle East and Africa Hepatocellular Carcinoma Drugs Market Size Outlook- continues its upward trajectory across segments

Robust demand from Middle Eastern countries including Saudi Arabia, the UAE, Qatar, Kuwait, and other GCC countries supports the overall Middle East Hepatocellular Carcinoma Drugs market potential. Fueled by increasing healthcare expenditure of individuals, growing population, and high prevalence across a few markets drives the demand for Hepatocellular Carcinoma Drugs.

Hepatocellular Carcinoma Drugs Market Company Profiles

The global Hepatocellular Carcinoma Drugs market is characterized by intense competitive conditions with leading companies opting for aggressive marketing to gain market shares. The report presents business descriptions, SWOT analysis, growth strategies, and financial profiles. Leading companies included in the study are Amgen Inc, AstraZeneca Plc, Bayer AG, Bristol-Myers Squibb Company, Celgene Corp, Eisai Co. Ltd, Exelixis Inc, F. Hoffmann-La Roche Ltd, Gilead Sciences Inc, GlaxoSmithKline

Plc, Hepion Pharmaceuticals, Janssen Global Services LLC, Eli Lilly and Company, Merck & Co, Pfizer Inc, Polaris Group, Provectus Biopharmaceuticals Inc, SillaJen Inc, Takeda Pharmaceutical Co. Ltd.

Recent Hepatocellular Carcinoma Drugs Market Developments

The global Hepatocellular Carcinoma Drugs market study presents recent market news and developments including new product launches, mergers, acquisitions, expansions, product approvals, and other updates in the industry.

Hepatocellular Carcinoma Drugs Market Report Scope

Parameters: Revenue, Volume Price

Study Period: 2023 (Base Year); 2018- 2023 (Historic Period); 2024- 2030 (Forecast Period)

Currency: USD; (Upon request, can be provided in Euro, JPY, GBP, and other Local Currency)

Qualitative Analysis

Pricing Analysis

Value Chain Analysis

SWOT Profile

Market Dynamics- Trends, Drivers, Challenges

Porter's Five Forces Analysis

Macroeconomic Impact Analysis

Case Scenarios- Low, Base, High

Market Segmentation:

By Type

Stationary 3D and 4D Ultrasound Devices

Portable 3D and 4D Ultrasound Devices

By Display

Color Ultrasound

B/W Ultrasound

By Portability

Trolley or Cart-Based Ultrasound Systems

Compact/Handheld Ultrasound Systems

Point-of-Pare (PoC) Ultrasound Systems

By Application

Radiology or General Imaging

Obstetrics or Gynecology

Cardiology

Urology

Vascular

Orthopedic and Musculoskeletal

Pain Management

Others

By End-User

Hospitals

Surgical Centers and Diagnostic Centers

Maternity Centers

Ambulatory Care Centers

Research and Academia

Others

Geographical Segmentation:

North America (3 markets)

Europe (6 markets)

Asia Pacific (6 markets)

Latin America (3 markets)

Middle East Africa (5 markets)

Companies

Amgen Inc

AstraZeneca Plc

Bayer AG

Bristol-Myers Squibb Company

Celgene Corp

Eisai Co. Ltd

Exelixis Inc

F. Hoffmann-La Roche Ltd

Gilead Sciences Inc

GlaxoSmithKline Plc

Hepion Pharmaceuticals

Janssen Global Services LLC

Eli Lilly and Company

Merck & Co

Pfizer Inc

Polaris Group

Provectus Biopharmaceuticals Inc

SillaJen Inc

Takeda Pharmaceutical Co. Ltd

Formats Available: Excel, PDF, and PPT

Contents

1. EXECUTIVE SUMMARY

- 1.1 Hepatocellular Carcinoma Drugs Market Overview and Key Findings, 2024
- 1.2 Hepatocellular Carcinoma Drugs Market Size and Growth Outlook, 2021- 2030
- 1.3 Hepatocellular Carcinoma Drugs Market Growth Opportunities to 2030
- 1.4 Key Hepatocellular Carcinoma Drugs Market Trends and Challenges
 - 1.4.1 Hepatocellular Carcinoma Drugs Market Drivers and Trends
 - 1.4.2 Hepatocellular Carcinoma Drugs Market Challenges
- 1.5 Competitive Landscape and Key Players
- 1.6 Competitive Analysis- Growth Strategies Adopted by Leading Hepatocellular Carcinoma Drugs Companies

2. HEPATOCELLULAR CARCINOMA DRUGS MARKET SIZE OUTLOOK TO 2030

- 2.1 Hepatocellular Carcinoma Drugs Market Size Outlook, USD Million, 2021- 2030
- 2.2 Hepatocellular Carcinoma Drugs Incremental Market Growth Outlook, %, 2021-2030
- 2.3 Segment Snapshot, 2024

3. HEPATOCELLULAR CARCINOMA DRUGS MARKET- STRATEGIC ANALYSIS REVIEW

- 3.1 Porter's Five Forces Analysis
 - * Threat of New Entrants
 - * Threat of Substitutes
 - * Intensity of Competitive Rivalry
 - * Bargaining Power of Buyers
 - * Bargaining Power of Suppliers
- 3.2 Value Chain Analysis
- 3.3 SWOT Analysis

4. HEPATOCELLULAR CARCINOMA DRUGS MARKET SEGMENTATION ANALYSIS AND OUTLOOK

- 4.1 Market Segmentation and Scope
- 4.2 Market Breakdown by Type, Application, and Other Segments, 2021-2030
 - By Type

Stationary 3D and 4D Ultrasound Devices
Portable 3D and 4D Ultrasound Devices
By Display
Color Ultrasound
B/W Ultrasound
By Portability
Trolley or Cart-Based Ultrasound Systems
Compact/Handheld Ultrasound Systems
Point-of-Pare (PoC) Ultrasound Systems
By Application
Radiology or General Imaging
Obstetrics or Gynecology
Cardiology
Urology
Vascular
Orthopedic and Musculoskeletal
Pain Management
Others
By End-User
Hospitals
Surgical Centers and Diagnostic Centers
Maternity Centers
Ambulatory Care Centers
Research and Academia
Others
4.3 Growth Prospects and Niche Opportunities, 2023- 2030
4.4 Regional comparison of Market Growth, CAGR, 2023-2030

5. REGION-WISE MARKET OUTLOOK TO 2030

5.1 Key Findings for Asia Pacific Hepatocellular Carcinoma Drugs Market, 2025
5.2 Asia Pacific Hepatocellular Carcinoma Drugs Market Size Outlook by Type, 2021-2030
5.3 Asia Pacific Hepatocellular Carcinoma Drugs Market Size Outlook by Application, 2021- 2030
5.4 Key Findings for Europe Hepatocellular Carcinoma Drugs Market, 2025
5.5 Europe Hepatocellular Carcinoma Drugs Market Size Outlook by Type, 2021- 2030
5.6 Europe Hepatocellular Carcinoma Drugs Market Size Outlook by Application, 2021-2030

- 5.7 Key Findings for North America Hepatocellular Carcinoma Drugs Market, 2025
- 5.8 North America Hepatocellular Carcinoma Drugs Market Size Outlook by Type, 2021- 2030
- 5.9 North America Hepatocellular Carcinoma Drugs Market Size Outlook by Application, 2021- 2030
- 5.10 Key Findings for South America Hepatocellular Carcinoma Drugs Market, 2025
- 5.11 South America Pacific Hepatocellular Carcinoma Drugs Market Size Outlook by Type, 2021- 2030
- 5.12 South America Hepatocellular Carcinoma Drugs Market Size Outlook by Application, 2021- 2030
- 5.13 Key Findings for Middle East and Africa Hepatocellular Carcinoma Drugs Market, 2025
- 5.14 Middle East Africa Hepatocellular Carcinoma Drugs Market Size Outlook by Type, 2021- 2030
- 5.15 Middle East Africa Hepatocellular Carcinoma Drugs Market Size Outlook by Application, 2021- 2030

6. COUNTRY-WISE MARKET SIZE OUTLOOK TO 2030

- 6.1 US Hepatocellular Carcinoma Drugs Market Size Outlook and Revenue Growth Forecasts
- 6.2 US Hepatocellular Carcinoma Drugs Industry Drivers and Opportunities
- 6.3 Canada Market Size Outlook and Revenue Growth Forecasts
- 6.4 Canada Hepatocellular Carcinoma Drugs Industry Drivers and Opportunities
- 6.6 Mexico Market Size Outlook and Revenue Growth Forecasts
- 6.6 Mexico Hepatocellular Carcinoma Drugs Industry Drivers and Opportunities
- 6.7 Germany Market Size Outlook and Revenue Growth Forecasts
- 6.8 Germany Hepatocellular Carcinoma Drugs Industry Drivers and Opportunities
- 6.9 France Market Size Outlook and Revenue Growth Forecasts
- 6.10 France Hepatocellular Carcinoma Drugs Industry Drivers and Opportunities
- 6.11 UK Market Size Outlook and Revenue Growth Forecasts
- 6.12 UK Hepatocellular Carcinoma Drugs Industry Drivers and Opportunities
- 6.13 Spain Market Size Outlook and Revenue Growth Forecasts
- 6.14 Spain Hepatocellular Carcinoma Drugs Industry Drivers and Opportunities
- 6.16 Italy Market Size Outlook and Revenue Growth Forecasts
- 6.16 Italy Hepatocellular Carcinoma Drugs Industry Drivers and Opportunities
- 6.17 Rest of Europe Market Size Outlook and Revenue Growth Forecasts
- 6.18 Rest of Europe Hepatocellular Carcinoma Drugs Industry Drivers and Opportunities

- 6.19 China Market Size Outlook and Revenue Growth Forecasts
- 6.20 China Hepatocellular Carcinoma Drugs Industry Drivers and Opportunities
- 6.21 India Market Size Outlook and Revenue Growth Forecasts
- 6.22 India Hepatocellular Carcinoma Drugs Industry Drivers and Opportunities
- 6.23 Japan Market Size Outlook and Revenue Growth Forecasts
- 6.24 Japan Hepatocellular Carcinoma Drugs Industry Drivers and Opportunities
- 6.26 South Korea Market Size Outlook and Revenue Growth Forecasts
- 6.26 South Korea Hepatocellular Carcinoma Drugs Industry Drivers and Opportunities
- 6.27 Australia Market Size Outlook and Revenue Growth Forecasts
- 6.28 Australia Hepatocellular Carcinoma Drugs Industry Drivers and Opportunities
- 6.29 South East Asia Market Size Outlook and Revenue Growth Forecasts
- 6.30 South East Asia Hepatocellular Carcinoma Drugs Industry Drivers and Opportunities
- 6.31 Rest of Asia Pacific Market Size Outlook and Revenue Growth Forecasts
- 6.32 Rest of Asia Pacific Hepatocellular Carcinoma Drugs Industry Drivers and Opportunities
- 6.33 Brazil Market Size Outlook and Revenue Growth Forecasts
- 6.34 Brazil Hepatocellular Carcinoma Drugs Industry Drivers and Opportunities
- 6.36 Argentina Market Size Outlook and Revenue Growth Forecasts
- 6.36 Argentina Hepatocellular Carcinoma Drugs Industry Drivers and Opportunities
- 6.37 Rest of South America Market Size Outlook and Revenue Growth Forecasts
- 6.38 Rest of South America Hepatocellular Carcinoma Drugs Industry Drivers and Opportunities
- 6.39 Middle East Market Size Outlook and Revenue Growth Forecasts
- 6.40 Middle East Hepatocellular Carcinoma Drugs Industry Drivers and Opportunities
- 6.41 Africa Market Size Outlook and Revenue Growth Forecasts
- 6.42 Africa Hepatocellular Carcinoma Drugs Industry Drivers and Opportunities

7. HEPATOCELLULAR CARCINOMA DRUGS MARKET OUTLOOK ACROSS SCENARIOS

- 7.1 Low Growth Case
- 7.2 Reference Growth Case
- 7.3 High Growth Case

8. HEPATOCELLULAR CARCINOMA DRUGS COMPANY PROFILES

- 8.1 Profiles of Leading Hepatocellular Carcinoma Drugs Companies in the Market
- 8.2 Business Descriptions, SWOT Analysis, and Growth Strategies

8.3 Financial Performance and Key Metrics

Amgen Inc

AstraZeneca Plc

Bayer AG

Bristol-Myers Squibb Company

Celgene Corp

Eisai Co. Ltd

Exelixis Inc

F. Hoffmann-La Roche Ltd

Gilead Sciences Inc

GlaxoSmithKline Plc

Hepion Pharmaceuticals

Janssen Global Services LLC

Eli Lilly and Company

Merck & Co

Pfizer Inc

Polaris Group

Provectus Biopharmaceuticals Inc

SillaJen Inc

Takeda Pharmaceutical Co. Ltd

9. APPENDIX

9.1 Scope of the Report

9.2 Research Methodology and Data Sources

9.3 Glossary of Terms

9.4 Market Definitions

9.5 Contact Information

I would like to order

Product name: Hepatocellular Carcinoma Drugs Market Size, Trends, Analysis, and Outlook By Drug Class (PD-1/PD-L1 Inhibitors, Atezolizumab, Avelumab, Durvalumab, Tyrosine Kinase Inhibitors, Gefitinib, Erlotinib, Sorafenib), By Treatment (Medication, Surgery, Radiotherapy, Chemotherapy, Others), By Route of Administration (Oral, Injectable, Others), By End-User (Hospitals, Homecare, Specialty Clinics, Others), By Distribution Channel (Hospital Pharmacy, Online Pharmacy, Retail Pharmacy), by Region, Country, Segment, and Companies, 2024-2030

Product link: <https://marketpublishers.com/r/H431FAF6D7BBEN.html>

Price: US\$ 3,980.00 (Single User License / Electronic Delivery)

If you want to order Corporate License or Hard Copy, please, contact our Customer Service:

info@marketpublishers.com

Payment

To pay by Credit Card (Visa, MasterCard, American Express, PayPal), please, click button on product page <https://marketpublishers.com/r/H431FAF6D7BBEN.html>

To pay by Wire Transfer, please, fill in your contact details in the form below:

First name:
Last name:
Email:
Company:
Address:
City:
Zip code:
Country:
Tel:
Fax:
Your message:

****All fields are required**

Customer signature _____

Please, note that by ordering from marketpublishers.com you are agreeing to our Terms & Conditions at <https://marketpublishers.com/docs/terms.html>

To place an order via fax simply print this form, fill in the information below and fax the completed form to +44 20 7900 3970